Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved...

Revolutionary Healing Technology for Treating Difficult and Chronic Wounds
Approved by Health Canada

TORONTO, June 6 /PRNewswire/ - Archimed, the woundcare division of Insense
Ltd., today announced it has received approval from Health Canada for the use
of its revolutionary Oxyzyme product in the treatment of difficult and chronic
wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the
world's leading wound care specialists, in 2004 by his team at the Toronto
Wound Healing Centres. The announcement was made at the 3rd Congress of the
World Union of Wound Healing Societies taking place from June 4-8, 2008 at the
Metro Toronto Convention Center.
Oxyzyme is a biochemical system in a dressing that ensures the oxygen in
the wound environment meets the diverse oxygen needs of the cells responsible
for healing. Ongoing clinical programs being undertaken in Europe are showing
that 20% of old, previously unhealable wounds (3.5 years) are now closing in
six weeks or under when dressed with Oxyzyme. Easy to use by any clinical
professional, Oxyzyme will now soon be available to the Canadian health care
system at a modest cost.
In conjunction with the announcement, Professor T.K. Hunt, often cited as
the father of modern wound care, was awarded a lifetime achievement award by
the World Union of Wound Healing Societies. Professor Hunt's insight and
discoveries on the role oxygen plays in the healing process was the
inspiration behind the development of Oxyzyme.
"The real value of Oxyzyme is that it combines two agents - iodine and
oxygen - that are essential to the process of wound healing and provides
further opportunities to overcome barriers to healing that may exist in the
patient," explained Dr. Keith Harding, leading figure in the international
wound care community and also a member of the World Union faculty. For more
information about Oxyzyme and Archimed visit www.archimed.co.uk.

About Insense Ltd.
------------------
Insense is a British biotechnology company founded by Professor Paul
Davis, Chief Scientific Officer, who led the team which invented and developed
the ClearBlue(TM) pregnancy test. The company is also developing products out
of its core technology for dermatology and health and beauty applications. For
more information about Insense Ltd. visit www.insense.co.uk.
SOURCE Insense Ltd.

Professor Paul Davis, Chief Scientific Officer, Founder, and Inventor,
Paul.davis@insense.co.uk, +44 7825 983 216